KYO Pharma (NASDAQ:OKYO) reported new exploratory Phase 2a findings for its lead candidate, urcosimod (0.05%), demonstrating that the topical therapy significantly improves the quality of life (QoL) for patients suffering from neuropathic corneal pain (NCP).
Aclaris Therapeutics (NASDAQ:ACRS) announced it has successfully completed patient enrollment for its Phase 2 clinical trial of bosakitug (ATI-045), an investigational treatment for patients suffering from moderate-to-severe atopic dermatitis.
Ovid Therapeutics (NASDAQ:IVID) announced a $60 million private placement to fund the expansion of its clinical pipeline into tuberous sclerosis complex seizures and infantile spasms.
Dogwood Therapeutics (NASDAQ:DWTX) reported its fourth-quarter and full-year 2025 financial results, highlighting a pivot toward late-stage clinical development for its lead analgesic candidate, Halneuron®.
Cingulate (NASDAQ:CING) announced its fourth-quarter and full-year 2025 financial results alongside several critical regulatory milestones on March 18, 2026.
InspireMD (NASDAQ:NSPR) reported a significant acceleration in its commercial operations for the fourth quarter of 2025, fueled by the successful U.S. market introduction of its CGuard Prime Carotid Stent System.
Biotech royalty aggregator XOMA Royalty 9NASDAQ:XOMA) reported a sharp financial turnaround for its 2025 fiscal year, swinging to a robust profit on the back of surging revenues and executing multiple shareholder-value initiatives.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) released new 24-week results from the highest dose cohort of its Phase 1b/2a RESOLVE trial, evaluating EP-104GI for the treatment of eosinophilic esophagitis (EoE).
Monte Rosa Therapeutics (NASDAQ:GLUE) reported a net loss of $46.1 million for the fourth quarter ended December 31, 2025.
High Tide (NASDAQ:HITI) reported its financial results for the first fiscal quarter ended January 31, 2026, marking its strongest start to a fiscal year to date.
Bicycle Therapeutics (NASDAQ:BCYC), a biotechnology firm pioneering "Bicycle" peptide technology, reported its fourth-quarter and full-year 2025 financial results on March 17, 2026.
Gyre Therapeutics (NASDAQ:GYRE) reached a critical regulatory milestone as the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) granted Priority Review status to the New Drug Application (NDA) for Hydronidone (F351).
